CoChat

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer

Open access

Abstract

Tamoxifen-based endocrine therapy remains a major adjuvant therapy for estrogen receptor (ER)-positive breast cancer (BC). However, many patients develop tamoxifen resistance, which results in recurrence and poor prognosis. Herein, we show that fatty acid oxidation (FAO) was activated in tamoxifen-resistant (TamR) ER-positive BC cells by performing bioinformatic and functional studies. We also reveal that CPT1A, the rate-limiting enzyme of FAO, was significantly overexpressed and that its enzymatic activity was enhanced in TamR cells. Mechanistically, the transcription factor c-Jun was activated by JNK kinase-mediated phosphorylation. Activated c-Jun bound to the TRE motif in the CPT1A promoter to drive CPT1A transcription and recruited CBP/P300 to chromatin, catalysing histone H3K27 acetylation to increase chromatin accessibility, which ensured more effective transcription of CPT1A and an increase in the FAO rate, eliminating the cytotoxic effects of tamoxifen in ER-positive BC cells. Pharmacologically, inhibiting CPT1A enzymatic activity with the CPT1 inhibitor etomoxir or blocking c-Jun phosphorylation with a JNK inhibitor restored the tamoxifen sensitivity of TamR cells. Clinically, high levels of phosphorylated c-Jun and CPT1A were observed in ER-positive BC tissues in patients with recurrence after tamoxifen therapy and were associated with poor survival. These results indicate that the assessment and targeting of the JNK/c-Jun-CPT1A-FAO axis will provide promising insights for clinical management, increased tamoxifen responses and improved outcomes for ER-positive BC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-023-06181-5

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 FAO confers tamoxifen resistance in ER-positive BC cells. a Venn diagram of overlapping genes significantly upregulated in tamoxifen-resistant (TamR) MCF7 and T47D cells identified in the GEO dataset GSE144378. b Gene Ontology analysis of the significantly enriched biological processes for 334 upregulated genes in both MCF7-TamR and T47D-TamR cells. c–e Comparison of CPT1 enzymatic activities (c), fatty acid oxidation (FAO) rates (d), and cellular ATP levels (e) between TamR and parental MCF7 and T47D cells. f, g RT-qPCR and western blot assessment of the mRNA (f) and protein (g) levels of CPT1A, CPT1B, and CPT1C in TamR and parental MCF7 and T47D cells. h Representative images for immunofluorescence analysis of CPT1A (green) in TamR and parental MCF7 cells. DAPI (blue) served as a marker for nuclei. i Comparison of CPT1 enzymatic activities in MCF7-TamR cells with or without etomoxir (ETX) treatment for 24 h. j CCK-8 analysis of MCF7-TamR cells treated with a concentration gradient of tamoxifen combined with or without ETX for 72 h. Unpaired Student’s t test in (c–f, i); ***P < 0.001.
Fig. 1 FAO confers tamoxifen resistance in ER-positive BC cells. a Venn diagram of overlapping genes significantly upregulated in tamoxifen-resistant (TamR) MCF7 and T47D cells identified in the GEO dataset GSE144378. b Gene Ontology analysis of the significantly enriched biological processes for 334 upregulated genes in both MCF7-TamR and T47D-TamR cells. c–e Comparison of CPT1 enzymatic activities (c), fatty acid oxidation (FAO) rates (d), and cellular ATP levels (e) between TamR and parental MCF7 and T47D cells. f, g RT-qPCR and western blot assessment of the mRNA (f) and protein (g) levels of CPT1A, CPT1B, and CPT1C in TamR and parental MCF7 and T47D cells. h Representative images for immunofluorescence analysis of CPT1A (green) in TamR and parental MCF7 cells. DAPI (blue) served as a marker for nuclei. i Comparison of CPT1 enzymatic activities in MCF7-TamR cells with or without etomoxir (ETX) treatment for 24 h. j CCK-8 analysis of MCF7-TamR cells treated with a concentration gradient of tamoxifen combined with or without ETX for 72 h. Unpaired Student’s t test in (c–f, i); ***P < 0.001.CC BY · PubMed Central
Fig. 2 c-Jun deletion restores tamoxifen sensitivity. a Top five transcription factors that regulate the expression of upregulated genes in TamR cells, as analysed by the ChEA3 web server. b Western blot assessment of c-Jun protein levels in TamR and parental MCF7 and T47D cells. c Pearson correlations between c-Jun mRNA levels and tamoxifen sensitivities in pan-cancer and BC cell lines. Pearson R = 0.129 for pan-cancer cell lines, and Pearson R = 0.286 for BC cell lines. AUC area under curve; a higher AUC indicates stronger cell viability under tamoxifen treatment; TPM transcripts per million. d Western blot experiments to validate the c-Jun knockout efficiency in both TamR and parental MCF7 and T47D cells. e CCK-8 analysis of TamR and parental MCF7 and T47D cells with or without c-Jun knockout treated with a concentration gradient of tamoxifen for 72 h. f Representative images of colony formation assays in TamR and parental MCF7 cells with or without c-Jun knockout treated with tamoxifen (10 μM) or vehicle and stained with crystal violet. g Quantification results of the colony formation assays in (f). Unpaired Student’s t test in (g); *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 2 c-Jun deletion restores tamoxifen sensitivity. a Top five transcription factors that regulate the expression of upregulated genes in TamR cells, as analysed by the ChEA3 web server. b Western blot assessment of c-Jun protein levels in TamR and parental MCF7 and T47D cells. c Pearson correlations between c-Jun mRNA levels and tamoxifen sensitivities in pan-cancer and BC cell lines. Pearson R = 0.129 for pan-cancer cell lines, and Pearson R = 0.286 for BC cell lines. AUC area under curve; a higher AUC indicates stronger cell viability under tamoxifen treatment; TPM transcripts per million. d Western blot experiments to validate the c-Jun knockout efficiency in both TamR and parental MCF7 and T47D cells. e CCK-8 analysis of TamR and parental MCF7 and T47D cells with or without c-Jun knockout treated with a concentration gradient of tamoxifen for 72 h. f Representative images of colony formation assays in TamR and parental MCF7 cells with or without c-Jun knockout treated with tamoxifen (10 μM) or vehicle and stained with crystal violet. g Quantification results of the colony formation assays in (f). Unpaired Student’s t test in (g); *P < 0.05, **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Fig. 3 c-Jun activates FAO to induce tamoxifen resistance. a Western blot analysis to detect the c-Jun overexpression in both wild-type MCF7 and T47D cells. b–d Comparison of CPT1 enzymatic activities (b), FAO rates (c), and cellular ATP levels (d) in wild-type MCF7 and T47D cells transfected with c-Jun overexpressing construct or empty vector. e CCK-8 analysis of c-Jun or empty vector transfected wild-type MCF7 and T47D cells which were treated with a concentration gradient of tamoxifen for 72 h. f CPT1 enzymatic activities in c-Jun-overexpressing wild-type MCF7 cells with or without ETX treatment for 24 h. g CCK-8 analysis of c-Jun-overexpressing wild-type MCF7 cells treated with a concentration gradient of tamoxifen combined with or without ETX for 72 h. Unpaired Student’s t test in (b–d, f); **P < 0.01, ***P < 0.001.
Fig. 3 c-Jun activates FAO to induce tamoxifen resistance. a Western blot analysis to detect the c-Jun overexpression in both wild-type MCF7 and T47D cells. b–d Comparison of CPT1 enzymatic activities (b), FAO rates (c), and cellular ATP levels (d) in wild-type MCF7 and T47D cells transfected with c-Jun overexpressing construct or empty vector. e CCK-8 analysis of c-Jun or empty vector transfected wild-type MCF7 and T47D cells which were treated with a concentration gradient of tamoxifen for 72 h. f CPT1 enzymatic activities in c-Jun-overexpressing wild-type MCF7 cells with or without ETX treatment for 24 h. g CCK-8 analysis of c-Jun-overexpressing wild-type MCF7 cells treated with a concentration gradient of tamoxifen combined with or without ETX for 72 h. Unpaired Student’s t test in (b–d, f); **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Fig. 4 c-Jun recruits the CBP/P300 to activate CPT1A transcription. a, b Western blot and RT-qPCR assessment of the protein (a) and mRNA (b) levels of CPT1A in wild-type MCF7 and T47D cells with or without c-Jun knockout. c Schematic diagram of the TRE motif location on the wild-type (WT) or mutant (MUT) promoter of CPT1A for luciferase reporter assays. TRE, TPA-responsive element. d HEK293T cells were transfected with empty vector or c-Jun-overexpressing plasmid to analyse the luciferase reporter activity driven by the WT or MUT CPT1A promoter. e Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) analysis of c-Jun occupancy on the CPT1A promoter region around the TRE motif in TamR and parental MCF7 and T47D cells. f STRING analysis of proteins interact with c-Jun. g Immunoprecipitation assay to confirm the interaction between c-Jun and CBP/P300 in T47D cells. h ChIP-qPCR assessment for the comparison of CBP, P300, and H3K27ac occupancy on the CPT1A promoter in MCF7 cells with or without c-Jun knockout. i HEK293T cells were transfected with empty vector, c-Jun-, CBP-, or P300-overexpressing plasmid alone or together as indicated to analyse the luciferase reporter activity driven by the WT CPT1A promoter. Unpaired Student’s t test in (b, e, h), and paired Student’s t test in (d, i); **P < 0.01, ***P < 0.001, n.s., not significant.
Fig. 4 c-Jun recruits the CBP/P300 to activate CPT1A transcription. a, b Western blot and RT-qPCR assessment of the protein (a) and mRNA (b) levels of CPT1A in wild-type MCF7 and T47D cells with or without c-Jun knockout. c Schematic diagram of the TRE motif location on the wild-type (WT) or mutant (MUT) promoter of CPT1A for luciferase reporter assays. TRE, TPA-responsive element. d HEK293T cells were transfected with empty vector or c-Jun-overexpressing plasmid to analyse the luciferase reporter activity driven by the WT or MUT CPT1A promoter. e Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) analysis of c-Jun occupancy on the CPT1A promoter region around the TRE motif in TamR and parental MCF7 and T47D cells. f STRING analysis of proteins interact with c-Jun. g Immunoprecipitation assay to confirm the interaction between c-Jun and CBP/P300 in T47D cells. h ChIP-qPCR assessment for the comparison of CBP, P300, and H3K27ac occupancy on the CPT1A promoter in MCF7 cells with or without c-Jun knockout. i HEK293T cells were transfected with empty vector, c-Jun-, CBP-, or P300-overexpressing plasmid alone or together as indicated to analyse the luciferase reporter activity driven by the WT CPT1A promoter. Unpaired Student’s t test in (b, e, h), and paired Student’s t test in (d, i); **P < 0.01, ***P < 0.001, n.s., not significant.CC BY · PubMed Central
Fig. 5 JNK-dependent c-Jun phosphorylation activates FAO. a Representative images for immunofluorescence analysis of phosphorylated c-Jun at the Ser63 site (pS63-c-Jun, red) in TamR and parental T47D cells. DAPI (blue) served as a marker for nuclei. b Western blot analysis showing the different levels of pS63-c-Jun in the cytoplasm and nuclei between TamR and parental MCF7 cells. c–f Comparison of CPT1A protein levels (c), CPT1A mRNA levels (d), cellular ATP levels (e), and FAO rates (f) in MCF7 cells transfected with empty vector, wild-type c-Jun construct (WT), or Ser63 phosphorylation disabled mutant form of c-Jun construct (S63A). g HEK293T cells were transfected with CPT1A luciferase reporter plasmids together with empty vector, WT c-Jun, or S63A c-Jun construct to analyse the luciferase reporter activity of the CPT1A promoter. h Representative images (left) and quantification results (right) of the colony formation assays for MCF7 cells transfected with empty vector, WT c-Jun, or S63A construct and treated with tamoxifen (10 μM) or vehicle. i Western blot assessment of the protein levels of pS63-c-Jun, total c-Jun, and JNK in nuclei of MCF7 cells treated with a concentration gradient of the JNK inhibitor SP600125 for 24 h. Unpaired Student’s t test in (d–f, h), and paired Student’s t test in (g); **P < 0.01, ***P < 0.001.
Fig. 5 JNK-dependent c-Jun phosphorylation activates FAO. a Representative images for immunofluorescence analysis of phosphorylated c-Jun at the Ser63 site (pS63-c-Jun, red) in TamR and parental T47D cells. DAPI (blue) served as a marker for nuclei. b Western blot analysis showing the different levels of pS63-c-Jun in the cytoplasm and nuclei between TamR and parental MCF7 cells. c–f Comparison of CPT1A protein levels (c), CPT1A mRNA levels (d), cellular ATP levels (e), and FAO rates (f) in MCF7 cells transfected with empty vector, wild-type c-Jun construct (WT), or Ser63 phosphorylation disabled mutant form of c-Jun construct (S63A). g HEK293T cells were transfected with CPT1A luciferase reporter plasmids together with empty vector, WT c-Jun, or S63A c-Jun construct to analyse the luciferase reporter activity of the CPT1A promoter. h Representative images (left) and quantification results (right) of the colony formation assays for MCF7 cells transfected with empty vector, WT c-Jun, or S63A construct and treated with tamoxifen (10 μM) or vehicle. i Western blot assessment of the protein levels of pS63-c-Jun, total c-Jun, and JNK in nuclei of MCF7 cells treated with a concentration gradient of the JNK inhibitor SP600125 for 24 h. Unpaired Student’s t test in (d–f, h), and paired Student’s t test in (g); **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Fig. 6 JNK inhibitors sensitise ER-positive BC cells to tamoxifen by inhibiting c-Jun-induced FAO. a, b Comparison of CPT1 enzymatic activities (a) and FAO rates (b) in MCF7 and T47D cells treated with the JNK inhibitor SP600125 (10 μM) or vehicle for 24 h. c Cell viability analysis for MCF7 and T47D cells treated with a concentration gradient of tamoxifen combined with SP600125 (10 μM) or vehicle for 72 h. IC50, half maximal inhibitory concentration. d Combination index-fraction affected plots of combined treatment of tamoxifen and SP600125 in MCF7 and T47D cells. Plots were generated using CompuSyn software. Combination index (CI) < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively. A smaller CI value indicates stronger synergism. e CCK-8 analysis for TamR and parental MCF7 and T47D cells treated with a concentration gradient of tamoxifen combined with SP600125 (10 μM) treatment or not for 72 h. f Representative data of tumours in nude mice bearing MCF7-TamR cells received different treatment, n = 6/group. g Statistical analysis of mouse tumour weight in different groups, n = 6/group. h Representative immunohistochemistry (IHC) staining for Ki-67 (upper) and pS63-c-Jun (lower) in formalin-fixed tumour sections from the indicated treatment groups. Scale bars = 50 μm. Unpaired Student’s t test in (a–c, g); ***P < 0.001.
Fig. 6 JNK inhibitors sensitise ER-positive BC cells to tamoxifen by inhibiting c-Jun-induced FAO. a, b Comparison of CPT1 enzymatic activities (a) and FAO rates (b) in MCF7 and T47D cells treated with the JNK inhibitor SP600125 (10 μM) or vehicle for 24 h. c Cell viability analysis for MCF7 and T47D cells treated with a concentration gradient of tamoxifen combined with SP600125 (10 μM) or vehicle for 72 h. IC50, half maximal inhibitory concentration. d Combination index-fraction affected plots of combined treatment of tamoxifen and SP600125 in MCF7 and T47D cells. Plots were generated using CompuSyn software. Combination index (CI) < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively. A smaller CI value indicates stronger synergism. e CCK-8 analysis for TamR and parental MCF7 and T47D cells treated with a concentration gradient of tamoxifen combined with SP600125 (10 μM) treatment or not for 72 h. f Representative data of tumours in nude mice bearing MCF7-TamR cells received different treatment, n = 6/group. g Statistical analysis of mouse tumour weight in different groups, n = 6/group. h Representative immunohistochemistry (IHC) staining for Ki-67 (upper) and pS63-c-Jun (lower) in formalin-fixed tumour sections from the indicated treatment groups. Scale bars = 50 μm. Unpaired Student’s t test in (a–c, g); ***P < 0.001.CC BY · PubMed Central
Fig. 7 c-Jun predicts tamoxifen therapy outcomes in ER-positive BC patients. a Representative IHC staining of pS63-c-Jun (upper) and CPT1A (lower) proteins in tumour tissues from ER-positive BC patients received tamoxifen therapy with or without recurrence after. b Statistical analysis of the histoscore of pS63-c-Jun (upper) and CPT1A (lower) proteins in tumour tissues from ER-positive BC patients received tamoxifen therapy with or without recurrence. NR, non-recurrence; R, recurrence. Unpaired Student’s t test; **P < 0.01. c Correlations between pS63-c-Jun and CPT1A protein levels in ER-positive BC tissues. Pearson correlation coefficient for statistical analysis. d The heatmap illustrates the association of different clinical characteristics in ER-positive BC patients with high and low expression of pS63-c-Jun. e The heatmap illustrates the association of different clinical characteristics in ER-positive BC patients with high and low expression of CPT1A. Statistical significance was assessed by the Chi-square test in (d, e). f Recurrence-free survival (RFS) was compared between patients with high and low expression of pS63-c-Jun. g RFS was compared between patients with high and low expression of CPT1A. Log-rank test in (f, g); HR, Hazard ratio. h Model depicting the role of the JNK/c-Jun-CPT1A-FAO axis in driving tamoxifen resistance in ER-positive BC.
Fig. 7 c-Jun predicts tamoxifen therapy outcomes in ER-positive BC patients. a Representative IHC staining of pS63-c-Jun (upper) and CPT1A (lower) proteins in tumour tissues from ER-positive BC patients received tamoxifen therapy with or without recurrence after. b Statistical analysis of the histoscore of pS63-c-Jun (upper) and CPT1A (lower) proteins in tumour tissues from ER-positive BC patients received tamoxifen therapy with or without recurrence. NR, non-recurrence; R, recurrence. Unpaired Student’s t test; **P < 0.01. c Correlations between pS63-c-Jun and CPT1A protein levels in ER-positive BC tissues. Pearson correlation coefficient for statistical analysis. d The heatmap illustrates the association of different clinical characteristics in ER-positive BC patients with high and low expression of pS63-c-Jun. e The heatmap illustrates the association of different clinical characteristics in ER-positive BC patients with high and low expression of CPT1A. Statistical significance was assessed by the Chi-square test in (d, e). f Recurrence-free survival (RFS) was compared between patients with high and low expression of pS63-c-Jun. g RFS was compared between patients with high and low expression of CPT1A. Log-rank test in (f, g); HR, Hazard ratio. h Model depicting the role of the JNK/c-Jun-CPT1A-FAO axis in driving tamoxifen resistance in ER-positive BC.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 66 references

Cited by

See all 37

Metadata

Authors
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S.
Affiliations
  • Union Hospital (CN)
  • Fujian Medical University (CN)
Corresponding author
  • Chen, Xiangjin
  • Xu, Sunwang
Venue
Cell Death & Disease
Published
2023-10-06
Volume
14
Issue
10
Pages
653-653
ISSN
2041-4889 (ISSN-L)
OpenAlex
W4387399646
Cited by
36
References
66
Citations by year
2026: 9 · 2025: 17 · 2024: 10
FWCI
4.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82103549, 82273367)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
tamoxifen resistance, estrogen receptor-positive breast cancer, fatty acid oxidation, c-Jun, JNK phosphorylation, CPT1A, endoplasmic reticulum stress, CBP/p300, histone H3K27 acetylation, chromatin accessibility, etomoxir, endocrine therapy resistance, tumor recurrence
MeSH terms
Breast Neoplasms, Chromatin, Fatty Acids, Female, Humans, Receptors, Estrogen, Tamoxifen, Gene Expression Regulation, Neoplastic, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. https://app.cochat.ai/papers/10.1038/s41419-023-06181-5
The paper
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023). Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. Cell Death & Disease. https://doi.org/10.1038/s41419-023-06181-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.